TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02316444

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Hepatitis B vaccine
Description: An eligible participant will receive 3 doses of hepatitis B vaccine ( 20mcg in the deltoid intramuscular). Then their immune response will be assessed. Non responders will receive 3 additional vaccine doses off protocol

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Hepatitis B vaccine
Description: An eligible participant will receive 3 doses of hepatitis B vaccine ( 20mcg in the deltoid intramuscular). Then their immune response will be assessed. Non responders will receive 3 additional vaccine doses off protocol
Study: NCT02798523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate(Solu-Medrol)
Description: Methylprednisolone sodium succinate for injection, USP (SOLU-MEDROL sterile powder, Pfizer, Inc.) is an anti-inflammatory glucocorticoid which occurs as a white, or nearly white, odorless hygroscopic, amorphous solid. It is very soluble in water and in alcohol; it is insoluble in chloroform and is very slightly soluble in acetone.~125-milligram Act-O-Vial (AOV) System: Each 2 mL AOV (when mixed) contains methylprednisolone sodium succinate equivalent to 125 milligrams methylprednisolone; also 1.6 mg monobasic sodium phosphate anhydrous; and 17.4 mg dibasic sodium phosphate dried.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate(Solu-Medrol)
Description: Methylprednisolone sodium succinate for injection, USP (SOLU-MEDROL sterile powder, Pfizer, Inc.) is an anti-inflammatory glucocorticoid which occurs as a white, or nearly white, odorless hygroscopic, amorphous solid. It is very soluble in water and in alcohol; it is insoluble in chloroform and is very slightly soluble in acetone.~125-milligram Act-O-Vial (AOV) System: Each 2 mL AOV (when mixed) contains methylprednisolone sodium succinate equivalent to 125 milligrams methylprednisolone; also 1.6 mg monobasic sodium phosphate anhydrous; and 17.4 mg dibasic sodium phosphate dried.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical methylprednisolone (Advantan emulsion 0 /1%)
Description: 1 g Advantan emulsion 0.1% (Bayer) contains methylprednisolone aceponate (21-acetoxy-11beta-hydroxy-6alpha-methyl-17-propionyloxy-1,4-pregnadiene-3,20-dione) 1 mg, as the active ingredient. It is an oil-in-water emulsion containing medium chain triglycerides, caprylic-capric-stearic triglyceride, polyoxyethylene alcohol 2-stearyl ether, polyoxyethylene alcohol-21-stearyl ether, benzyl alcohol, disodium edetate, glycerol, and purified water.
Study: NCT02481765

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High definition transcranial direct current stimulation
Study: NCT00469508

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: 400mg pills taken orally daily for 12 wks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400mg pills taken orally daily for 12 wks
Study: NCT00723658

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous-autologous tandem hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study: NCT02024464

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrus Microstent
Description: Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iStent Trabecular Micro Bypass
Description: Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract removal and intraocular lens (IOL) implantation
Description: Cataract removal with phacoemulsification using standard techniques, followed by implantation with a posterior-chamber IOL suitable for glaucoma subjects

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract removal and intraocular lens (IOL) implantation
Description: Cataract removal with phacoemulsification using standard techniques, followed by implantation with a posterior-chamber IOL suitable for glaucoma subjects
Study: NCT00964418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: 0.4 U/kg body weight injected s.c. (subcutaneously) once daily for 6 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: 0.4 U/kg body weight injected s.c. (subcutaneously) once daily for 6 days
Study: NCT03235908

Intervention type: OTHER
Intervention: Observation only
Description: Observation only
Study: NCT01134510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1 Esterase Inhibitor
Description: C1 Esterase Inhibitor 20 units/kg twice weekly x 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: NS (comparable volume as intervention) twice weekly x 4wks
Study: NCT04403438

Intervention type: OTHER
Intervention: ıt will be compared pain, sleep, fatigue, physical activity level and quality of life and questioning exercise habits before and after the covid-19 outbreak in patients with Behçet and FMF.
Description: ıt will be compared pain, sleep, fatigue, physical activity level and quality of life and questioning exercise habits before and after the covid-19 outbreak in patients with Behçet and FMF.
Study: NCT04634123

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulpotomy therapy by White Portland Cement
Description: Carious asymptomatic primary anterior teeth will be removed of dental caries likely to produce vital pulp exposure . The access will be refined using a sterile no. 4 or 6 round bur in a slow-speed handpiece . The remaining pulp will be treated using pulpotomy therapy by White Portland Cement

Intervention type: OTHER
Group type: OTHER
Intervention: Pulpotomy therapy by White MTA
Description: Carious asymptomatic primary anterior teeth will be removed of dental caries likely to produce vital pulp exposure . The access will be refined usinga sterile no. 4 or 6 round bur in a slow-speed handpiece . The remaining pulp will be treated using pulpotomy therapy by White MTA
Study: NCT03751202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg
Description: 2 inhalations of Test and Reference product in each study period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADVAIR DISKUS
Description: 2 inhalations of Test and Reference product in each study period
Study: NCT00629824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon alpha and plus ribavirin
Description: pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day, 24weeks of treatment for genotype non-1 infected patients and 48 weeks of treatment for genotype 1 infected patients, follow up for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon alpha and plus ribavirin
Description: pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day, 24weeks of treatment for genotype non-1 infected patients and 48 weeks of treatment for genotype 1 infected patients, follow up for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon alpha and plus ribavirin
Description: pegylated interferon alpha 180 ug/week and ribavirin 1000-1200 mg/day for 24 weeks
Study: NCT01565486

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasonic coagulation device (Harmonic ACE® scalpel)
Description: Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy

Intervention type: DEVICE
Group type: OTHER
Intervention: bipolar energy sealing system (LigaSure Precise)
Description: Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
Study: NCT01111370

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DexCom™ G4 Continuous Glucose Monitoring System
Description: Continuous Glucose Monitoring System
Study: NCT00177489

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multicomponent psychosocial intervention
Description: The intervention addressed caregiver depression, burden, self-care, and social support and care recipient problem behaviors through 12 in-home and telephone sessions over 6 months.

Intervention type: OTHER
Group type: OTHER
Intervention: Control arm
Description: Caregivers in the control group received 2 brief check-in telephone calls during the 6-month intervention.
Study: NCT03448835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: atezolizumab 1200 mg 5 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: capecitabine 850 mg /m2 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: oxaliplatin 100 mg/m2 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: docetaxel 50 mg/m2 4 cycles
Study: NCT03995771

Intervention type: OTHER
Intervention: Questionnaire delivery
Description: A questionnaire including questions regarding prognostic factors for knee pain will be delivered to children and adolescents (8-19 years old) presenting to general practice with knee pain
Study: NCT03040050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rPCR results
Description: Interventional group: rPCR results will be shared with the clinical provider to determine appropriate standard of care antibiotic treatment at time of standard of care prostate biopsy.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Control group: rPCR results will not be shared with the clinical provider at time of standard of care prostate biopsy. Standard of care antibiotic selection will be up to the discretion of the clinical provider.
Study: NCT00666185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: IV
Study: NCT03227926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab 20 MG/ML Intravenous Solution [VECTIBIX]
Description: Panitumumab 6 mg/kg in 100 cc 0.9% NaCl solution on Day 1 every two weeks by IV administration over 1 hour.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Molecular Screening
Description: Patients without plasmatic evidence of potentially resistant clones harbouring RAS or EGFR-ectodomain mutations in the RML liquid biopsy, will be molecular eligible for the trial phase
Study: NCT02261740

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Therapy
Description: A 90-minute orientation session led by the yoga class instructors, followed by 90-minute group yoga classes twice weekly for 6 weeks. Classes will be led by an experienced instructor. Women will also be taught to avoid any habits that may worsen their genito-pelvic pain (e.g., straining their pelvic floor muscles).~Participants will also be asked to practice yoga at home an additional hour per week throughout the 6-week yoga therapy program. Participants will be given a detailed written manual to use for home practice.
Study: NCT03168061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC 6300
Description: Part 1: NC-6300 at escalating doses starting at a fixed dose Part 2: NC-6300 at the RPII dose
Study: NCT04204681

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography imaging
Description: This study aimed to measure the tongue areas of the patients two times both of study and control groups with ultrasonography imaging to compare the tongue areas.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography imaging
Description: This study aimed to measure the tongue areas of the patients two times both of study and control groups with ultrasonography imaging to compare the tongue areas.
Study: NCT03237208

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: Transcutaneous electrical nerve stimulation (TENS) treatment will be activated.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: placebo group
Description: Transcutaneous electrical nerve stimulation treatment will not be activated.
Study: NCT04215692

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pulmonary ultrasound
Description: Pulmonary ultrasound is a basic application of critical ultrasound, defined as a loop associating urgent diagnoses with immediate therapeutic decisions.
Study: NCT00645242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluconazole
Description: Fluconazole oral suspension 6 mg/kg/day for 6 weeks followed by 4 weeks without treatment
Study: NCT01513018

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high tidal volumes
Description: One-lung ventilation was started at skin incision using a volume-controlled square-wave flow pattern. Patients were randomly assigned to 30 minutes of ventilation with a tidal volume of 10 ml/kg tidal volume without external PEEP and respiratory rate of 10 breaths/minute (n=50) or to a tidal volume of 5 ml/kg with 5 cmH2O PEEP and a respiratory rate of 20 breaths/minute (n=50). Minute volume was thus kept constant during each experimental condition.~Randomization was based on computer-generated codes that were maintained in sequentially numbered sealed opaque envelopes until after induction of anesthesia. During the subsequent 30 minutes of one-lung ventilation, the alternative ventilatory management was used.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low tidal volume
Description: One-lung ventilation was started at skin incision using a volume-controlled square-wave flow pattern. Patients were randomly assigned to 30 minutes of ventilation with a tidal volume of 10 ml/kg tidal volume without external PEEP and respiratory rate of 10 breaths/minute (n=50) or to a tidal volume of 5 ml/kg with 5 cmH2O PEEP and a respiratory rate of 20 breaths/minute (n=50). Minute volume was thus kept constant during each experimental condition.~Randomization was based on computer-generated codes that were maintained in sequentially numbered sealed opaque envelopes until after induction of anesthesia. During the subsequent 30 minutes of one-lung ventilation, the alternative ventilatory management was used.
Study: NCT01042301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samplings

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood samplings

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samplings

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samplings

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samplings

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samplings
Study: NCT03767738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept Injection (IAI)
Description: IAI prepared and administered with a pre-filled syringe (PFS)
Study: NCT03887572

Intervention type: OTHER
Intervention: MOVIN
Description: MOVIN is a multi-component unit-based intervention comprised of five components that are implemented simultaneously in a hospital unit. The five components are: 1) psychomotor skills training, 2) unit ambulation culture, 3) communication, 4) resources, 5) ambulation environment.
Study: NCT02057835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 691751
Description: Placebo to BI 691751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 691751 low dose 1
Description: BI 691751 low dose 1
Study: NCT00103727

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo Comparator

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: Active Comparator
Study: NCT01767831

Intervention type: BEHAVIORAL
Intervention: iBOLUSED
Description: The intervention will involve daily diary data upload and daily simulation-based feedback based on the collected diary data. Throughout the educational intervention, participants will record diary data every day through the use of a diary component in the internet-based system. Diary entries include data on meals, physical activity, history of the insulin basal rate and insulin boluses given that day, self-reported stress level, hypo- and hyperglycemic fear levels, and, if applicable, menstrual cycle and any physical illness. Participants will also upload data from the CGM via the Dexcom DM3 software or the Dexcom Studio Software.

Intervention type: BEHAVIORAL
Intervention: iBOLUSED
Description: The intervention will involve daily diary data upload and daily simulation-based feedback based on the collected diary data. Throughout the educational intervention, participants will record diary data every day through the use of a diary component in the internet-based system. Diary entries include data on meals, physical activity, history of the insulin basal rate and insulin boluses given that day, self-reported stress level, hypo- and hyperglycemic fear levels, and, if applicable, menstrual cycle and any physical illness. Participants will also upload data from the CGM via the Dexcom DM3 software or the Dexcom Studio Software.
Study: NCT02875574

Intervention type: DRUG
Intervention: Any treatment regimen
Description: Treatment regimen used to treat patient once isoniazid resistance known (exposure of interest for cohort study)

Intervention type: OTHER
Intervention: Bacterial mutation
Description: Resistance, compensatory or other mutation in the infecting strain of Mycobacterium tuberculosis (exposure of interest for nested case-control study)
Study: NCT04668378

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time restricted eating
Description: TRE subjects consumed 100 % of their energy needs divided into three meals consumed at 1 p.m., 4 p.m. and 8 p.m., and fasted for the remaining 16 h per 24-h period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time restricted eating
Description: TRE subjects consumed 100 % of their energy needs divided into three meals consumed at 1 p.m., 4 p.m. and 8 p.m., and fasted for the remaining 16 h per 24-h period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Diet
Description: ND group ingested their caloric intake as three meals consumed at 8 a.m., 1 p.m. and 8 p.m.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Diet
Description: ND group ingested their caloric intake as three meals consumed at 8 a.m., 1 p.m. and 8 p.m.
Study: NCT01183858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib [Tarceva]
Description: Single daily oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib [Tarceva]
Description: Single daily oral dose
Study: NCT03127020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PQR309
Description: taken continuously on daily basis (60mg, 80mg) or intermittent dosing (120mg, 140mg, 160mg)
Study: NCT02417415

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive heat stress
Description: Passive heat stress will be applied with a commercial heating pad that covers all the abdomen and part of the torso to provide local heating at \~44ºC continuously for 2 hr.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control (non-heating)
Description: Heating pad will be applied over the abdomen and part of the torso but it will be turned off.
Study: NCT02975323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Single dose of oral carvedilol 12.5 mg and wait till the time there's 20% reduction in hepatic wedge pressure gradient from the baseline.
Study: NCT06074172

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol in Oral Dose Form
Description: Cannabidiol press pills provided by Steve Goods CBD (Longmont, Colorado). CBD pills were tested by the chemistry lab at CSU Pueblo and by Botanacor in Denver, CO. Both laboratories determined CBD pills to be 99.98% pure with no THC, heavy metals, bacteria, and pesticides detected.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in Oral Dose Form
Description: Placebo press pills provided by Steve Goods CBD (Longmont, Colorado). Placebo pills were tested by the chemistry lab at CSU Pueblo and by Botanacar in Denver, CO. Both laboratories determined placebo pills to be pure with no heavy metals, bacteria, and pesticides detected.
Study: NCT01047787

Intervention type: OTHER
Intervention: Polysomnography
Description: examination for sleep disorders
Study: NCT01386671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin glycinate
Description: Drug: Metformin glycinate 12 months: 1 month,one tablet 1050.6 mg once daily + 11 months, one tablet 1050.6 mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin hydrochloride
Description: 12 months: 1 month, once daily dose of 850 mg (before dinner) and 11 months, twice daily dose 850 mg (before breakfast) + 850 mg (before dinner).
Study: NCT02437669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: To be administered by intranasal route using mucosal atomization device.
Study: NCT05736315

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo dairy beverage
Description: Placebo dairy beverage (placebo) is a sweetened dairy beverage.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo dairy beverage
Description: Placebo dairy beverage (placebo) is a sweetened dairy beverage.
Study: NCT04754373

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GFA-918
Description: Participants will be instructed to take one GFA-918 (125000 FIP Units of Lipase AY) capsule twice per day with their morning and evening meals for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be instructed to take one Placebo capsule twice per day with their morning and evening meals for 12 weeks.
Study: NCT04560127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab combination with Apatinib
Description: Apatinib (250mg p.o. q.d.) combined with Camrelizumab (200mg, iv, q2w)